The normalization of testosterone decline in men is one of the most consequential failures of modern medicine. Every year, millions of men present to their physicians with fatigue, low libido, decreased strength, poor recovery, cognitive fog, and depression — and are told their testosterone is "normal for their age." This is technically accurate. It is also clinically inadequate.
The Reference Range Problem — Again
Total testosterone reference ranges in males typically span from 264 to 916 ng/dL. A man at 270 ng/dL is technically normal. So is a man at 900 ng/dL. Their subjective experience, body composition, cognitive function, and quality of life may be profoundly different. The question that matters is not whether you fall within the range — it is whether your level is optimal for your biology and your health goals.
The 264–916 ng/dL range was established from a general male population that includes elderly men, men with chronic illness, men on medications that suppress testosterone, and men who are simply not in good health. It represents a wide band of "what exists in the population," not "what is associated with good health outcomes."
Research on symptom resolution and health outcomes consistently shows that most men feel and function optimally with total testosterone above 600–700 ng/dL and free testosterone in the upper quartile of the reference range. Many men presenting with classic low-testosterone symptoms have total testosterone in the 300–450 ng/dL range — technically normal, functionally deficient.
What Low Testosterone Actually Feels Like
The symptoms of testosterone deficiency in men are frequently attributed to aging, stress, or depression — and treated accordingly with antidepressants, sleep aids, or lifestyle advice, when the root cause is hormonal. Classic symptoms include:
Persistent fatigue not improved by sleep. Reduced motivation, drive, and competitive edge. Decreased libido and sexual function. Increased body fat, particularly abdominal. Loss of muscle mass despite consistent training. Slowed recovery from exercise. Cognitive fog, difficulty concentrating, poor memory. Irritability, low mood, reduced emotional resilience. Decreased bone density over time.
Testosterone Replacement Therapy: The TRAVERSE Trial
The largest safety trial of testosterone replacement in men — the TRAVERSE trial, published in the New England Journal of Medicine in 2023 — followed 5,246 men with hypogonadism and elevated cardiovascular risk for a median of 33 months. The primary finding: testosterone therapy did not increase the risk of major adverse cardiovascular events compared to placebo.
This is significant because cardiovascular risk was the primary safety concern that had made many physicians reluctant to prescribe TRT for decades. The TRAVERSE trial largely put that concern to rest in appropriately selected patients.
Treatment Options
Testosterone replacement is available in multiple forms: topical gels (Androgel, Testim), transdermal patches, injectable testosterone cypionate or enanthate (self-administered weekly or biweekly), subcutaneous pellets, and nasal gel. Each has different pharmacokinetics, adherence profiles, and effects on hematocrit, fertility (TRT suppresses sperm production — a critical consideration for men desiring future fertility), and estradiol conversion.
The choice of delivery method should be individualized based on your goals, lifestyle, and clinical picture — not defaulted to whatever the prescribing physician is most comfortable with. A hormone specialist will evaluate all options and match the protocol to your specific situation.
When Not to Treat
TRT is not appropriate for men with untreated severe sleep apnea, prostate cancer, significantly elevated hematocrit, or who desire future fertility without fertility-preservation strategies. Each of these situations requires specific management. An appropriate evaluation will identify contraindications and address them as part of the treatment plan.